Literature DB >> 1998971

Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor.

H Hirte1, D A Clark.   

Abstract

The effect of cell-free ascitic fluid from patients with epithelial ovarian carcinoma on the generation of lymphokine-activated killer cells (LAK) was compared to the activity generated in control medium containing 10% fetal bovine serum, using Daudi target cells. Samples of ascitic fluid from nine different patients tested inhibited LAK generation. Suppressive activity was evident as early as 24 h of incubation in the presence of ascitic fluid and increasing suppression developed with prolonged exposure. Suppression was concentration-dependent, present at 10%-20% and increasing with concentrations up to 80%. The suppressive effect of ascitic fluid was only partially reversed on increasing the concentration of interleukin-2 (IL-2) from 10 units to 1000 units/ml. Activated LAK appeared to maintain the majority of their activity on further culture in ascitic fluid in the presence of IL-2 but further enhancement of lytic activity was prevented. Fractionation of a suppressive sample by HPLC, using 0.1 M KCl/acetic acid buffer pH 2.6, revealed that the dominant peak of suppressive activity eluted at 25 kDa; with pH 7.0 TRIS-buffered saline, most of the activity was lost on the column. Antibody neutralization studies of the 25-kDa suppressive peak as well as on whole ascitic fluid have revealed that transforming growth factor beta (TGF beta) is the major suppressive factor present in ascitic fluid. Factors that suppress LAK generation in vitro were present in all samples tested. The effect on the lytic activity of activated LAK cells was minimal. This suggests that, in the clinical setting, the greatest impact would be achieved by activating LAK cells ex vivo and subsequently transferring them to the peritoneal cavity in the presence of IL-2 rather than by attempting to generate them in situ by injecting IL-2 into the peritoneal cavity. However, reversal of TGF beta-mediated suppression in situ may be necessary to allow local proliferation of LAK cells to achieve an effective killer-to-target ratio.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1998971     DOI: 10.1007/bf01789047

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  34 in total

1.  The regulatory effect of adherent cells on lymphokine activated killer cells.

Authors:  Y Ibayashi; D S Hoon; S H Golub
Journal:  Cell Immunol       Date:  1987-12       Impact factor: 4.868

Review 2.  Lymphokine-activated killer lymphocytes: evidence for regulation of induction and function by multiple cytokines.

Authors:  L B Owen-Schaub; E A Grimm
Journal:  Immunol Ser       Date:  1989

3.  Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients.

Authors:  K Itoh; N R Pellis; C M Balch
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Increased secretion of type beta transforming growth factor accompanies viral transformation of cells.

Authors:  M A Anzano; A B Roberts; J E De Larco; L M Wakefield; R K Assoian; N S Roche; J M Smith; J E Lazarus; M B Sporn
Journal:  Mol Cell Biol       Date:  1985-01       Impact factor: 4.272

5.  Partial purification and characterization of a lymphocyte-inhibitory factor(s) in ascitic fluids from ovarian cancer patients.

Authors:  A D Hess; S A Gall; J R Dawson
Journal:  Cancer Res       Date:  1980-06       Impact factor: 12.701

6.  Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

Authors:  R Lafreniere; S A Rosenberg
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

Review 7.  Effects of tumor growth on host defenses.

Authors:  G J Cianciolo; R Snyderman
Journal:  Cancer Metastasis Rev       Date:  1986       Impact factor: 9.264

8.  Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients.

Authors:  K Tamura; Y Shibata; Y Matsuda; N Ishida
Journal:  Cancer Res       Date:  1981-08       Impact factor: 12.701

9.  Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity.

Authors:  H F Pross; M G Baines; P Rubin; P Shragge; M S Patterson
Journal:  J Clin Immunol       Date:  1981-01       Impact factor: 8.317

10.  Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells.

Authors:  J J Mulé; S L Schwarz; A B Roberts; M B Sporn; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

View more
  9 in total

1.  Oncolytic virotherapy for ovarian cancer.

Authors:  Shoudong Li; Jessica Tong; Masmudur M Rahman; Trevor G Shepherd; Grant McFadden
Journal:  Oncolytic Virother       Date:  2012-08

2.  Effects of CD4+ and CD8+ T cells in tumor-bearing mice on antibody production.

Authors:  M Shimizu; T Iwaguchi
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

Review 3.  The immunobiological effects of interleukin-2 in vivo.

Authors:  R A Janssen; N H Mulder; T H The; L de Leij
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

4.  Transforming growth factor-beta synthesis by human peritoneal mesothelial cells. Induction by interleukin-1.

Authors:  F A Offner; H Feichtinger; S Stadlmann; P Obrist; C Marth; P Klingler; B Grage; M Schmahl; C Knabbe
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

5.  Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor beta inhibition of lymphokine-activated killer cell generation.

Authors:  J Koberda; E A Grimm; R P Moser
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

6.  Progression mechanisms in colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumour stage correlations.

Authors:  A M Berghella; P Pellegrini; D Piancatelli; D Maccarone; T Del Beato; D Giubilei; A Pomidori; D Adorno; C U Casciani
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

7.  Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy.

Authors:  H Fakhrai; O Dorigo; D L Shawler; H Lin; D Mercola; K L Black; I Royston; R E Sobol
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

8.  In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.

Authors:  D R Negri; E Tosi; O Valota; S Ferrini; A Cambiaggi; S Sforzini; A Silvani; P A Ruffini; M I Colnaghi; S Canevari
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

9.  Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma.

Authors:  Maurizio Ghisoli; Minal Barve; Reva Schneider; Robert Mennel; Carl Lenarsky; Gladice Wallraven; Beena O Pappen; John LaNoue; Padmasini Kumar; Derek Nemunaitis; Alyssa Roth; James Nemunaitis; Sam Whiting; Neil Senzer; Frederick A Fletcher; John Nemunaitis
Journal:  Mol Ther       Date:  2015-03-19       Impact factor: 11.454

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.